Isomorphic Labs Raises $600 Million in Series A to Advance AI-Driven Drug Discovery

On March 31, in London, Isomorphic Labs, an AI-first drug design and development company, announced that it had raised $600 million in its first round of external financing. The round was led by Thrive Capital, with participation from GV, and follow-on funding from existing investor Alphabet.

Isomorphic Labs was established to leverage the power of artificial intelligence to reimagine and accelerate drug discovery, bringing much-needed treatments to millions of patients worldwide. The company aims to apply its groundbreaking AI-driven drug design engine to achieve biomedical breakthroughs and advance drug design projects across multiple therapeutic areas and drug modalities.。（$3 Billion! Lilly and Novartis Each Reach AI Drug Discovery Collaboration）

Demis Hassabis, founder and CEO of Isomorphic Labs, said:"We are thrilled to bring together a top group of investors with deep expertise in artificial intelligence and life sciences as we aim to transform this industry through an interdisciplinary approach. This funding will further advance the development of our next-generation AI-driven drug design engine, helping us push our own projects into clinical development, marking a significant step toward our mission of one day solving all diseases with the help of AI."

Since its establishment, the company has developed numerous next-generation artificial intelligence models, which, when combined, form its unified AI drug design engine capable of operating across multiple therapeutic areas and drug modalities. A groundbreaking model is AlphaFold 3, developed byIsomorphic Labs and Google DeepMind jointly developed and released in May 2024, capable of accurately predicting the structure and interactions of all biomolecules. Utilizing these state-of-the-art artificial intelligence technologies,Isomorphic Labs has established a drug discovery portfolio, which includes collaboration projects with pharmaceutical industry leaders Eli Lilly and Novartis, as well as internal projects primarily focused on oncology and immunology. Novartis andIsomorphic Labs recently expanded the initial scope of collaboration more than a year after establishing the partnership.

Joshua Kushner, founder and CEO of Thrive Capital, said:"At Thrive, our goal is to invest in category-defining companies with unique beliefs, which prompted us to establishIsomorphic Labs. We believe that Isomorphic has earned a rare position in defining a new era of drug discovery and design, and we are deeply inspired by their mission and the extraordinary progress they have made so far."

This investment will accelerate Isomorphic Labs' cutting-edge artificial intelligence R&D to rapidly advance the company's next-generation AI drug design engine. As part of the next phase of growth,Isomorphic Labs will expand its world-class talent team.

GV managing partner Krishna Yeshwant, M.D., said:"Artificial intelligence and machine learning have long held the promise of transforming drug discovery, but in the past decade, few companies have been able to fully realize their potential. Having witnessed...Following Isomorphic Labs' extraordinary pace of innovation, we believe their groundbreaking approach will redefine AI-driven drug discovery. Under the leadership of Demis Hassabis, Isomorphic has assembled an exceptional team at the intersection of life sciences and technology. We are proud to support their advancement in the development of new therapies for patients."